Tirzepatide contraindications: who should not use it

Last updated 2026-07-27

What are the absolute contraindications to tirzepatide?

There are two hard contraindications listed in the FDA prescribing information for both Mounjaro and Zepbound, and they're not negotiable. The first is a personal or family history of medullary thyroid carcinoma (MTC). The second is Multiple Endocrine Neoplasia syndrome type 2 (MEN2), a rare inherited condition that carries a high lifetime risk of MTC. The label states plainly: tirzepatide is "contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)" ^[1]. This isn't a caution or a "talk to your doctor" item. It's a boxed warning, the FDA's strongest label designation, reserved for risks that are serious or life-threatening. The third absolute contraindication is simpler: a prior serious hypersensitivity reaction to tirzepatide itself or any component of the formulation. If you've had anaphylaxis or angioedema on a previous dose, you don't rechallenge. That one's common sense, but it's on the label for a reason ^[1]. If you don't know your family thyroid cancer history, that's worth finding out before you start, not after. A single conversation with a parent or sibling about whether anyone in the family has had thyroid cancer, and what kind, can settle this in five minutes.

Why does tirzepatide carry a thyroid cancer boxed warning?

The warning traces back to rodent studies, not to a confirmed pattern in humans on this drug specifically. In rats and mice given tirzepatide, researchers saw dose- and duration-dependent increases in thyroid C-cell tumors, including MTC ^[1]. This is a known class effect across GLP-1 receptor agonists, not something unique to tirzepatide; liraglutide's label carries the same boxed warning, and it's been there since Victoza was approved in 2010. The honest answer on human relevance: nobody knows for certain, because C-cell tumors are rare and slow-growing, and rodent thyroid C-cells respond to GLP-1 receptor activation more sensitively than human ones do. The FDA's position is that the mechanism is "unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans" ^[1], which is why the label uses cautious, not confirmatory, language. Long-term thyroid cancer surveillance data in tirzepatide users specifically is still accumulating; the drug has only been on the market since 2022 for diabetes and 2023 for weight loss, and MTC is a disease that can take years to show up in registries. What this means practically: if you don't have a personal or family history of MTC or MEN2, your baseline risk from this specific warning is low, but it's also not zero-risk science, it's a precaution built on animal data and an abundance of caution given how rare and serious MTC is when it does occur.

Who should avoid tirzepatide because of pancreatitis risk?

Acute pancreatitis is listed as a warning, not an absolute contraindication, but it changes the calculus for anyone with a prior episode. In the SURMOUNT-1 trial, acute pancreatitis was reported in a small number of participants on tirzepatide versus placebo, and the drug's label instructs prescribers to observe patients for signs of pancreatitis (persistent, severe abdominal pain, sometimes radiating to the back, with or without vomiting) and to discontinue tirzepatide if pancreatitis is suspected ^[1][2]. If you've had a prior episode of pancreatitis, especially one not clearly caused by something else (like gallstones that have since been removed, or heavy alcohol use that's stopped), this is a conversation to have before starting, not a hard no automatically. Prescribers weigh the cause of the prior episode, how severe it was, and whether the underlying trigger is resolved. GLP-1/GIP receptor agonists as a class have carried a pancreatitis signal in postmarketing reports for over a decade, going back to exenatide and liraglutide. The SURPASS program (the T2D trials) and SURMOUNT program (the weight-loss trials) both tracked this prospectively, and neither showed a dramatically elevated rate compared to placebo, but the numbers are small enough that a definitive causal link one way or the other isn't settled.

Does tirzepatide cause gallbladder problems?

Yes, gallbladder disease shows up clearly in the trial data, and it's one of the more common serious adverse events tied to tirzepatide use. In SURMOUNT-1, cholelithiasis (gallstones) occurred in about 2.6% of participants on the higher tirzepatide doses versus roughly 1% on placebo over 72 weeks ^[2]. Cholecystitis (gallbladder inflammation) and cases requiring cholecystectomy (gallbladder removal surgery) were also reported. The mechanism isn't a direct toxic effect on the gallbladder. It's downstream of rapid weight loss. Losing weight quickly, especially more than about 1.5 kg per week, is a well-established risk factor for gallstone formation regardless of what caused the weight loss, because rapid fat loss changes the cholesterol concentration in bile ^[3]. Since tirzepatide can produce faster and larger weight loss than older obesity drugs, gallbladder issues become more visible in the data. Anyone with a history of gallstones or a prior cholecystectomy isn't automatically excluded from tirzepatide, but new or worsening right upper abdominal pain, especially after fatty meals, deserves a prompt call to your prescriber, not a wait-and-see approach.

Can people with a history of diabetic retinopathy take tirzepatide?

This one is more nuanced than a flat contraindication. Rapid improvement in blood glucose control, from any diabetes medication, can transiently worsen diabetic retinopathy in the short term. This is a known phenomenon documented with insulin and other glucose-lowering therapies, not unique to tirzepatide, but the SURPASS program did track retinopathy-related adverse events. In the SURPASS-2 trial (tirzepatide vs. semaglutide, NCT03987919), diabetic retinopathy complications were monitored as an adverse event category, and the tirzepatide label notes patients with a history of diabetic retinopathy should be monitored for progression ^[1]. This isn't a reason to avoid the drug outright if you have T2D and existing retinopathy, but it is a reason to keep up with routine eye exams during the first several months of treatment, when glucose drops fastest. If you have proliferative diabetic retinopathy or a recent retinal event, this is worth flagging to both your endocrinologist and your ophthalmologist before starting, since the rate of glucose improvement matters more than the drug class itself.

Is tirzepatide safe during pregnancy or breastfeeding?

No adequate human data exists, and the label reflects that gap honestly rather than claiming safety. Animal reproduction studies showed adverse effects on fetal development at doses relevant to human exposure, and the FDA label states there is insufficient data on tirzepatide use in pregnant women to evaluate a drug-associated risk ^[1]. Because tirzepatide causes significant weight loss and reduced caloric intake, which can pose risks during pregnancy independent of any direct drug effect, both Mounjaro and Zepbound labeling recommend discontinuing the drug in patients who become pregnant. If you're planning a pregnancy, the practical move is to stop tirzepatide with your provider's guidance before you start trying, given that oral contraceptive efficacy can also be affected by tirzepatide's effect on gastric emptying, particularly at treatment initiation and dose escalation. For breastfeeding, there's no data on whether tirzepatide passes into human milk, and the label states this isn't known, so the standard advice is to weigh the mother's clinical need against any potential unknown risk to the infant with your provider ^[1].

Is tirzepatide safe for children or teenagers?

Neither Mounjaro nor Zepbound is FDA-approved for anyone under 18. Safety and efficacy in pediatric patients haven't been established through the trial programs that led to approval, and there's no pediatric dosing on either label ^[1][4]. This is different from some other obesity medications: semaglutide (Wegovy) does have a pediatric indication down to age 12, approved in December 2022 based on the STEP TEEN trial. Tirzepatide doesn't have equivalent approved pediatric data yet, though clinical trials in adolescents were underway as of the most recent label updates. Until that data matures and the FDA acts on it, tirzepatide in anyone under 18 is off-label territory with an evidence gap, more than a regulatory technicality.

What about kidney disease, liver disease, or heart conditions?

Tirzepatide isn't contraindicated in renal or hepatic impairment, and no dose adjustment is required based on kidney or liver function according to the FDA label ^[1]. That's a genuine advantage over some other diabetes drugs (metformin, for instance, has real renal dosing cutoffs). Clinical trials included patients across a range of kidney function, and pharmacokinetic studies didn't show clinically meaningful differences requiring dose changes. That said, the GI side effects (nausea, vomiting, diarrhea) that come with tirzepatide can cause dehydration, and dehydration can worsen kidney function acutely in anyone already vulnerable, particularly older patients or those on diuretics. The label specifically notes that acute kidney injury has been reported, usually in the setting of vomiting, diarrhea, or dehydration, and recommends monitoring renal function in patients reporting severe adverse GI reactions ^[1]. On the cardiovascular side, tirzepatide's heart-related data is actually reassuring rather than concerning. The SURPASS-CVOT trial (NCT04255433) compared tirzepatide to insulin degludec in T2D patients with elevated cardiovascular risk and found tirzepatide was non-inferior to degludec for major adverse cardiovascular events (MACE) ^[5]. There's no cardiac contraindication on the label. Patients with a history of heart failure or coronary disease aren't excluded, though anyone with a serious active cardiac condition should have that discussion with their cardiologist and prescriber jointly.

What are the most common side effects that aren't contraindications?

Most people who stop tirzepatide do so because of GI side effects, not because they hit a true contraindication. In SURMOUNT-1, nausea occurred in roughly 25-31% of participants depending on dose, diarrhea in about 15-17%, constipation in about 11-17%, and vomiting in about 8-13%, generally concentrated during dose escalation ^[2]. In SURPASS-2, similar GI patterns showed up, with nausea around 12-22% and diarrhea around 12-17% across the 5, 10, and 15 mg doses ^[6]. These aren't reasons to avoid tirzepatide outright, but they are reasons dosing is escalated slowly. Most GLP-1/GIP regimens start at 2.5 mg weekly and step up every 4 weeks, precisely because the GI effects are worst at each dose increase and tend to fade as the body adjusts. If you're mapping out your own schedule, the Tirz Rx dosage guide and the Tirz Rx dosage calculator walk through the standard titration steps in more detail. Severe or persistent vomiting and diarrhea deserve a call to your prescriber regardless of whether they cross into pancreatitis or kidney injury territory, simply because dehydration on top of appetite suppression is a real combination risk, especially in the first two months.

How is compounded tirzepatide different from Mounjaro or Zepbound for contraindications?

The contraindications themselves (MTC/MEN2 history, prior hypersensitivity reaction) apply to the tirzepatide molecule, not to the brand, so they hold regardless of whether the product is FDA-approved Mounjaro/Zepbound or compounded tirzepatide from a state-licensed pharmacy. But there's a meaningful difference in what you actually know about the product you're injecting. Mounjaro and Zepbound went through FDA review of manufacturing, purity, and consistent dosing as part of approval. Compounded tirzepatide, by definition, has not been FDA-approved as a finished product; compounding pharmacies operate under different rules (503A or 503B of the Federal Food, Drug, and Cosmetic Act) that don't require the same premarket efficacy and safety trials ^[7]. The FDA has published warnings about compounded tirzepatide products found to contain incorrect salt forms (tirzepatide salts, as opposed to the base compound used in the approved drugs) and inconsistent dosing between vials . This matters for contraindications in a practical sense: if you can't be sure of the exact concentration in a vial, you can't be fully sure you're avoiding an unintentional overdose, which raises the stakes on GI side effects and dehydration risk even in someone with no other contraindications. Anyone using compounded product should get it from a pharmacy that's transparent about sourcing, lab testing, and dosing accuracy, and should work with a provider who reviews your health history against the same contraindication list that applies to the branded drugs. If you're reconstituting or dosing compounded tirzepatide yourself, the how to reconstitute Tirz Rx and Tirz Rx how to inject guides cover the technical steps, and getting injection technique right also reduces local site reactions that can otherwise get confused with more serious problems.

What questions should you ask your provider before starting tirzepatide?

A short, direct checklist covers most of what matters. Do I or does anyone in my immediate family have a history of medullary thyroid carcinoma or MEN2? Have I ever had pancreatitis, and if so, was the cause identified and resolved? Do I have gallstones or a history of gallbladder disease? Am I pregnant, trying to become pregnant, or breastfeeding? Do I have diabetic retinopathy, and when was my last eye exam? Have I had a prior serious allergic reaction to tirzepatide or a similar drug? A provider-reviewed approach means someone actually checks these boxes against your history before you start, and adjusts the plan (site rotation, injection sites, cycle length) based on your answers rather than a generic protocol. Tirz Rx works with a provider-reviewed model, connecting patients to licensed prescribers who screen for these exact contraindications, with fulfillment handled through a licensed pharmacy partner, rather than shipping product with no clinical review attached. If you've cleared the screening and are moving into an actual regimen, the Tirz Rx injection sites and Tirz Rx cycle length guides are the logical next stops for getting the mechanics right.

Frequently asked questions

What is the boxed warning on tirzepatide for?

The boxed warning covers thyroid C-cell tumors, including medullary thyroid carcinoma, based on findings in rodent studies. The FDA states it's unknown whether this happens in humans, but as a precaution, tirzepatide is contraindicated in anyone with a personal or family history of MTC or MEN2 syndrome ^[1].

Can I take tirzepatide if a family member had thyroid cancer?

It depends on the type. The contraindication specifically covers medullary thyroid carcinoma (MTC) and MEN2 syndrome, not all thyroid cancers. Papillary or follicular thyroid cancer in a family member isn't the same contraindication, but tell your prescriber the exact diagnosis so they can confirm it's not MTC-related.

Is tirzepatide safe if I've had gallstones before?

A prior history of gallstones isn't an absolute contraindication, but it raises your risk since rapid weight loss on tirzepatide increases gallstone formation. In SURMOUNT-1, cholelithiasis occurred in about 2.6% of tirzepatide users versus about 1% on placebo over 72 weeks ^[2]. Report new upper right abdominal pain promptly.

Does tirzepatide cause pancreatitis?

Acute pancreatitis has been reported in tirzepatide trials, though at low rates, and it's listed as a warning rather than a strict contraindication. A prior pancreatitis episode doesn't automatically rule you out, but your prescriber will want to know the cause and whether it's resolved before starting ^[1][2].

Can people with kidney disease take tirzepatide?

Yes, no dose adjustment is required for renal impairment per the FDA label. The real risk is indirect: GI side effects like vomiting and diarrhea can cause dehydration, which can stress already-reduced kidney function, so hydration and symptom reporting matter more than the diagnosis itself ^[1].

Is tirzepatide safe during pregnancy?

No. There's insufficient human data to evaluate risk, and animal studies showed adverse fetal effects at clinically relevant doses. Standard guidance is to discontinue tirzepatide if you become pregnant or are planning pregnancy, and to discuss backup contraception since GI slowing can affect oral contraceptive absorption ^[1].

Can teenagers or children use tirzepatide?

No FDA-approved pediatric indication exists for Mounjaro or Zepbound as of the current label. Safety and efficacy under age 18 haven't been established through completed trials, unlike semaglutide (Wegovy), which has an approved pediatric indication starting at age 12 ^[1][4].

What's the difference between contraindications for compounded tirzepatide versus Zepbound?

The clinical contraindications (MTC/MEN2 history, prior severe allergic reaction) are the same because it's the same molecule. The difference is regulatory: compounded tirzepatide isn't FDA-approved as a finished product, and the FDA has flagged inconsistent dosing and incorrect salt forms in some compounded versions ^[7][8].

Does tirzepatide worsen diabetic eye disease?

Rapid glucose improvement from any diabetes drug can transiently worsen diabetic retinopathy, and this was tracked in the SURPASS trials. It's not a contraindication, but patients with existing retinopathy should keep up routine eye exams, especially in the first several months of treatment when glucose drops fastest ^[1].

Is tirzepatide safe for people with heart disease?

There's no cardiac contraindication on the label. The SURPASS-CVOT trial (NCT04255433) found tirzepatide non-inferior to insulin degludec for major cardiovascular events in high-risk T2D patients, which is reassuring data rather than a red flag ^[5].

What allergic reactions can happen with tirzepatide?

Hypersensitivity reactions including anaphylaxis and angioedema have been reported. A prior serious allergic reaction to tirzepatide is an absolute contraindication to using it again. Milder injection site reactions (redness, itching) are common and not the same as a systemic allergic reaction.

Should I stop tirzepatide before surgery?

Tirzepatide slows gastric emptying, which has raised anesthesia concerns about aspiration risk during procedures requiring sedation. Many anesthesia and surgical protocols now recommend holding GLP-1/GIP drugs for a period before elective procedures; timing should be confirmed with your surgical and prescribing teams directly rather than assumed.

Sources

1. FDA, Zepbound (tirzepatide) Prescribing Information: Boxed warning on MTC/MEN2 contraindication, pancreatitis, pregnancy, renal/hepatic dosing, and hypersensitivity language
2. NEJM, SURMOUNT-1 trial results (Jastreboff et al., 2022): Rates of cholelithiasis, GI adverse events, and pancreatitis reporting in the SURMOUNT-1 tirzepatide obesity trial
3. NIDDK, Gallstones: Rapid weight loss is a known risk factor for gallstone formation
4. ClinicalTrials.gov, SURPASS-CVOT (NCT04255433): SURPASS-CVOT compared tirzepatide to insulin degludec for cardiovascular outcomes in T2D patients
5. NEJM, SURPASS-2 trial results (Frias et al., 2021): GI adverse event rates (nausea, diarrhea) across tirzepatide doses in the SURPASS-2 T2D trial
6. FDA, Medications Containing Semaglutide/Tirzepatide Marketed for Weight Loss: FDA warnings about compounded GLP-1/GIP products with incorrect salt forms and dosing inconsistencies
7. ClinicalTrials.gov, SURPASS-2 (NCT03987919): SURPASS-2 trial identifier comparing tirzepatide to semaglutide in T2D patients